Dabogratinib clinical trials
Also written TYRA-300.
How each study uses dabogratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dabogratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TYRA-300
- 2
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Tyra Biosciences, Inc (5)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test dabogratinib.
- Nov 2026Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsPhase 1/2 · Tyra Biosciences, Inc
Studies
Open first, then newest update. How each study uses dabogratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaRecruitingPhase 2Tyra Biosciences, IncNCT07265947Written as Dabogratinib (TYRA-300) 60mg
- Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingPhase 2Tyra Biosciences, IncNCT06995677Written as TYRA-300 60mg
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301RecruitingPhase 2Tyra Biosciences, IncNCT06842355Written as TYRA-300 0.125 mg/kg
- Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsActive, not recruitingPhase 1/2Tyra Biosciences, IncNCT05544552Written as TYRA-300
- A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult ParticipantsActive, not recruitingPhase 1Tyra Biosciences, IncNCT06006702Written as TYRA-300-B01
Codes
What other systems call dabogratinib · ClinicalTrials.gg INT016560
- UNII (FDA) FH245S2JZJDABOGRATINIBConfirmed FDA, Wikidata
- Wikidata Q140528739dabogratinibConfirmed FDA, Wikidata
- NCI Thesaurus C190779DabogratinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FH245S2JZJ | DABOGRATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140528739 | dabogratinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190779 | Dabogratinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.